Prucalopride: safety, efficacy and potential applications
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Chronic constipation is a very common functional gastrointestinal disorder which can be associated with significant impairments in quality of life for some people with the condition. Its management has, traditionally, been based on dietary and lifestyle changes and the use of a variety of laxative agents. The evidence base for the efficacy of the latter is, in many cases, slim. Not surprisingly, many patients remain dissatisfied with laxatives thus leading to the development of more pharmacological approaches. Among these approaches is the use of prokinetic agents; while prior molecules have been troubled by lack of selectivity and cardiac side effects, the new agent, prucalopride, appears to be highly selective for the serotonin 5-HT4 receptor and is, therefore, a potent stimulator of gut motility. In three large pivotal randomized controlled trials, prucalopride has been effective in relieving the cardinal symptoms of chronic constipation; these effects have been sustained in open-label follow up for as long as 18 months. The safety profile has been encouraging and, especially so, the absence of arrhythmogenic potential. Studies in men, in constipation-predominant irritable bowel syndrome and in other motor disorders are eagerly awaited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198 · cited 1×
“Constipation is at least twice as common in women as in men and its occurrence increases with advancing age, particularly after age 65 [Drossman et al. 1993; Talley et al. 1992; Sonnenberg and Koch, 1989].”
BackgroundAn Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
A placebo-controlled trial of prucalopride for severe chronic constipation
Camilleri, M., Kerstens, R., Rykx, A., & Vandeplassche, L. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800670 · Cited by 576 · cited 8×
“Where reported, the prevalence of serious adverse events was similar for placebo and prucalopride [Tack et al. 2009; Quigley et al. 2009; Camilleri et al. 2008b].”
BackgroundResultInfluentialDROSSMAN, D. A., CHEY, W. D., JOHANSON, J. F., FASS, R., SCOTT, C., PANAS, R., & UENO, R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03881.x · Cited by 399 · cited 2×
“Both have demonstrated efficacy in CC and CIBS [Johnston et al. 2010; Lembo et al. 2010; Drossman et al. 2009; Johanson et al. 2008a, 2008b].”
BackgroundQUIGLEY, E. M. M., VANDEPLASSCHE, L., KERSTENS, R., & AUSMA, J. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03884.x · Cited by 344
Self-citationJohnston, J. M., Kurtz, C. B., MacDougall, J. E., Lavins, B. J., Currie, M. G., Fitch, D. A., O'Dea, C., Baird, M., & Lembo, A. J. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.041 · Cited by 229
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225 · cited 1×
“Irritable bowel syndrome (IBS) is one of the most common disorders encountered in modern medicine; community surveys in Western Europe and North America suggesting a prevalence of around 10% in the adult population [Brandt et al. 2009; Quigley et al. 2007].”
BackgroundSelf-citationDi Palma, J. A., Cleveland, M. V., McGowan, J., & Herrera, J. L. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01365.x · Cited by 84
Cited by
Chronic constipation: A review of literature
Forootan, M., Bagheri, N., & Darvishi, M. (2018) · Medicine · doi:10.1097/md.0000000000010631 · Cited by 364
Metoclopramide for the treatment of diabetic gastroparesis
Shakhatreh, M., Jehangir, A., Malik, Z., & Parkman, H. P. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1645594 · Cited by 83
Cinca, R., Chera, D., Gruss, H. ‐., & Halphen, M. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12278 · Cited by 73
Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction
Leppert, W. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s32684 · Cited by 72
“The most common AE comprise headache (25%–30% of treated patients), nausea (12%–24%), abdominal cramps (16%–23%), and diarrhea (12%–19%).(52) A phase-2 controlled study conducted during 4 weeks in 196 patients with noncancer pain and OIC found an increase in the number of complete spontaneous BM in patients treated wi…”
BackgroundGastrointestinal medication burden among persons with the Ehlers‐Danlos syndromes
Dhingra, R., Bascom, R., Thompson, E., Francomano, C. A., & Schubart, J. R. (2021) · Neurogastroenterology & Motility · doi:10.1111/nmo.14077 · Cited by 7
Metadata
- Authors
- Quigley, E. M. M.
- Venue
- Therapeutic Advances in Gastroenterology
- Publisher
- SAGE Publications
- Published
- 2011-10-06
- Volume
- 5
- Issue
- 1
- Pages
- 23-30
- ISSN
- 1756-283X (ISSN-L)
- 1756-2848
- OpenAlex
- W2135918186
- Cited by
- 66
- References
- 9
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prucalopride: safety, efficacy and potential applications. https://app.cochat.ai/papers/10.1177/1756283x11423706
- The paper
- Quigley, E. M. M. (2012). Prucalopride: safety, efficacy and potential applications. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/1756283x11423706
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.